



The United Laboratories International Holdings Limited

L)

Interim Results 2007

September 2007









Section 1 Major Accomplishments in 1H2007











Results Overview



- Successfully listed on the main board of Hong Kong Stock Exchange on 15 Jun 2007
 - 26.87 times over-subscribed for retail tranche, substantially oversubscribed for placing tranche
 - US\$121.4 million raised
- Impressive results in 1H2007
 - Turnover and net profit surged 28% and 108% respectively
- New product, Adefovir dipivoxil capsules, launched in September 2007 and received satisfactory market response
- Average selling price of bulk medicine significantly increased by 58% due to strong market demand

Section 2 Business review











1 Growing Sales Volume of Group's Products



Types	Products	Sales volume in 1H 2007	Sales volume in 1H 2006	yoy growth
Intermediate products (tonne)	6-APA	215.2	390.4	-45%
Bulk medicine (tonne)	Semi-synthetic penicillin type	1,442.0	1,228.0	+17%
	Cephalosporins type	306.5	427.8	-28%
	$\boldsymbol{\beta}$ - lactamase inhibitor type	32.5	4.0	+713%
Finished products	Amoxicillin granules (pack)	1,709	1,416	+21%
	Tazobactam sodium and piperacillin sodium for injectior (2.25g) (pack)	ר 7,550	5,153	+46.5%
	Cephalosporins for Injection (pack)	8,754	1,693	+417.1%
	Amoxicillin capsules (250mg)	6,484	6,790	-5%
	Ampicillin capsules (250mg)	8,508	8,751	-3%

2 Rising Average Selling Price



	1H2007	1H2006	yoy growth
Intermediate products(RMB/kg)			
• 6-APA	269.4	170.3	+ 58%
Bulk medicine (RMB/kg)			
 Semi-synthetic penicillin type 	290.9	190.7	+53%
Cephalosporins type	836.5	811.3	+3%
• β - lactamase inhibitor type	980.3	1,538.7	-36%
Finished products (RMB/package)			
 Semi-synthetic penicillin antibiotics 			
 Ampicillin capsules (250mg) 	11.2	10.2	+10%
– Amoxicillin capsules (250mg)	10.3	9.2	+12%
 Amoxicillin capsules (500mg x 24 capsules) 	17.7	16.2	+10%
– Amoxicillin granules	6.8	6.1	+11%

* All prices were excluding VAT

3 Expanding Production Capacity



	1H2007	
	(Designed Capacity)	Rate
Intermediate products (tonnes)		
• 6-APA	1,733.5	69%
Bulk medicine (tonnes)		
 Semi-synthetic penicillin type 	1,884	94%
Cephalosporins type	331	53%
Finished products		
Amoxicillin & Ampicillin capsules	593 mil	93%
Amoxicillin granules	23 mil	83%
• β - lactamase inhibitor antibiotics (bottle)	5.24 mil	79%

Extensive Sales and Distribution Network



Success in the development of sales inside and outside the PRC

Sales inside the PRC

- Over 1,600 sales people in 24 sales offices as at 30 June 2007
- Direct contact with hospitals and pharmacies

Sales outside the PRC

- Total sales outside of PRC accounted for 25% of the Group total sales in 1H2007 (1H2006:19.8%, 2006: 21.4%)
- Sales of intermediate products and bulk medicine to Germany, Korea and India



5 Diversified Customer Base Attributable to Quality Products



Customers	Certification		
Finished products	GMP		
	 All bulk medicine and finished products production facilities are GMP certified 		
SPH L 13 M L Shanghai Pioneer Huakang Pharmaceutical Company Limited	Drug Registration Approvals		
上海新先鋒華康醫藥有限公司	Drug Registration Approvals from FDA (U.S.) (applying)		
	European Directorate for the Quality of Medicines (EDQM)		
Bulk medicine	(applying)		
	PRC brands with excellent quality		
	Awards		
	Received many awards in recognition of its excellent product quality		
	Recognised as an Enterprise of Advanced New Technology		
PHARMACEUTICAL CO., LTD.	Individual pricing		
	5 products have awarded with Individual Pricing		

6 Environmental Engineering



- The Group has established waste water treatment facilities at both its production plants in Zhuhai and Chengdu to meet with applicable national environmental standards
- Closely monitors the performance of its environmental facilities to ensure compliance with national and local regulatory standards

Section 3 Financial Highlights















Revenue

ப

Revenue Breakdown by Products



Finished Products




TUL benefits stable supply to downstream production, costs efficiency and flexibility from it vertical integration

Business Segment Results & Margins



(HK\$m)



	Margins		
	1H 2007	1H 2006	
Intermediate products	5.4%	4.5%	
Bulk medicine	24.2%	4.9%	
Finished products	22.7%	28.3%	

Gross Profit





EBITDA, Gross profit and Gross profit margin (HK\$m) 800 50.0% 700 736.3 43.7% 45.0% 35.4% 600 40.0% 599.8 500 <mark>531.2</mark> 33.2% 35.0% **501.3** 36.2% 34.9% 400 399.5 30.0% 337.7 343.2 300 348.8 282.2 25.0% 200 232.0 20.0% 100 15.0% 0 2004 2005 2006 1H2006 1H2007 Gross Profit **EBITDA** Gross Profit Margin

Profit Attributable to Shareholders & EPS



Profit Attributable to Shareholders





Other Key Financial Indicators



	As at 30 Jun 2007	As at 31 Dec 2006
Trade and bills receivable turnover (days)	99.0	131.8
Trade and bills payable turnover (days)	186.4	210.0
Current ratio	1.23	1.00
Gearing ratio ⁽¹⁾	29.0%	39.5%
Cash and cash equivalents (HK\$ '000)	859,213	99,226
Total assets (HK\$ '000)	4,136,720	3,712,220

(1) Gearing ratios are calculated by dividing total debts by total assets and multiplying the quotient by 100

Section 4 Strategies & Outlook











Outlook for 2H2007



Market Outlook

- Domestic market:
 - pharmaceutical industry will experience abundant growth despite rising cost pressure
 - Expanding medical coverage to more urban and rural areas
 - In an advantageous position to grasp the opportunities arising from market consolidation
- Overseas market:
 - Growing demand for bulk medicine and intermediate products

Promising New Drug Pipeline



New Products

Product	Classification	Main curative effects	Expected time for obtaining drug registration approval
Adefovir dipivoxil capsules (阿德福韋酯膠囊)	Nucleotide antivivotic	For treatment of hepatitis B	1H 2007
Isophane protamine human insulin injection (精蛋白人胰島素注射液)	Bio product	For treatment of type I & II diabeties	2008
Imipenem cilastatin sodium for injection (注射用亞胺培南西司他丁鈉)	our paperierris	For treatment of various types of infection	2008
Meropenem for injection (注射用美羅培南)	Carbapenems antibiotics	For treatment of various types of injection	2008
Major research projects			
Research partner	Research project	Current Status	
SFDA Sichuan Antibiotics Industry Research Centre	Development for the treatment of hepatitis B	Application made for production approval in the PRC	
Xgen Laboratories	Development of therapeutic vaccines against Tumor	Pre-clinical testing stage	
Chengdu Yatu Biotechnology Co., Ltd.	Development of orlistat	Application made for commencement of clinical testing in the PRC	

26 finished products under development at various stages

Strategies in 2H 2007



Strategies

- Expansion of intermediate production capacity to maximise the benefits of large scale production and vertical integration
- To establish a new intermediate production plant in Inner Mongolia, increasing production capacity of 6-APA
- Enhance R&D capability and introduce new products to expand revenue stream
- Stringent cost control and further improve product mix to improve production effectiveness and profitability

Vision

Become the leading and the largest generic antibiotics manufacturing enterprise in the PRC offering a wide spectrum of high quality products

Section 5 Q & A Session









